The sensitivity of prostate-specific antigen (PSA) for screening prostate cancer scored 80-82% with a cut-off level of 4.0 ng/mL (3-5), which is much higher than for digital rectal examination (DRE) (4) and transrectal ultrasound (TURS) (3,5). This evidence concerns the gene KLK3 and prostate carcinoma.